---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000694"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:21:45.146254+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Genprex advances diabetes gene therapy GPX-002 into T2D preclinical studies, plans FDA meeting Q1 2026

## Summary
- Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.
- Submitted meeting request to FDA for Q1 2026 to discuss IND-enabling studies for GPX-002.
- Transferred GPX-002 manufacturing to experienced CDMO; plans clinical-scale cGMP production.
- Continuing construct optimization for second-generation GPX-002 using non-viral lipid nanoparticle delivery.
- Toxicology studies to follow FDA interaction; data expected to enable IND filing.

## SEC filing metadata
- accession: 0001437749-26-000694
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926000694/0001437749-26-000694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926000694/gnpx20260105_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000694
- JSON: https://secwatch.observer/filing/0001437749-26-000694.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.